Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.010
-0.020 (-0.99%)
At close: Nov 20, 2024, 4:00 PM
1.960
-0.050 (-2.49%)
After-hours: Nov 20, 2024, 5:05 PM EST
Can-Fite BioPharma Employees
Can-Fite BioPharma had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$83,375
Profits / Employee
-$921,375
Market Cap
14.75M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vivos Therapeutics | 123 |
| Psychemedics | 116 |
| Cumberland Pharmaceuticals | 91 |
| Microbot Medical | 22 |
| Traws Pharma | 18 |
| Minerva Neurosciences | 9 |
| Autonomix Medical | 8 |
| PharmaCyte Biotech | 2 |
CANF News
- 10 days ago - Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewsWire
- 17 days ago - Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia - GlobeNewsWire
- 4 weeks ago - Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson - GlobeNewsWire
- 6 weeks ago - FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health - GlobeNewsWire
- 3 months ago - Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies - GlobeNewsWire
- 3 months ago - OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 3 months ago - Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds - GlobeNewsWire